Medicus Pharma Ltd. (MDCX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 72/100 (HIGH), 5.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 7.35% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Medicus Pharma Outlines Clinical Development Strategy Across Three Drug Programs Following $90 Million in Financing
- Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances
- Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
- Medicus Pharma seeks FDA alignment on streamlined Phase 2b/3 Teverelix study
- Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA
- Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
- Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
- Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Medicus Pharma Ltd..
Full MDCX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.